- Management, R&D team boasts decades of industry leadership
- Pipeline includes therapies targeting chronic pain, nausea, inflammation, muscle spasms, epilepsy and Post Traumatic Stress Disorder
- Unique result-driven strategy strongly positions Veritas in the medical marijuana industry
Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is an emerging pharmaceutical and IP development company publicly traded in Canada, the United States and Germany. Through its recently acquired 80 percent stake in Cannevert Therapeutics Ltd., also known as Veritas’ R&D arm, the company is clinically profiling various marijuana cultivars to pharmacologically connect unique strains with specific disease conditions. Veritas Pharma’s goal is to perform clinical trials to prove the efficacy of the designated lead cannabis strains and to market the clinically effective cultivars as prescription medicines in a fast-track protocol.
Veritas Pharma’s management and R&D team comprises decades of pharmaceutical, clinical and scientific research expertise into several key industry leaders. Lui Franciosi, PhD, who has over 20 years of experience conducting pharmaceutical and medical device studies in academia and industry, leads the company as its CEO. In addition to a team of trained technicians and students working out of academic facilities, Veritas Pharma is pleased to have a renowned group of scientists on board to lead its research efforts. Team members hold 10 PhDs/MD licenses with expertise in chemistry, pharmacology and clinical trials.
Veritas Pharma’s mission is to develop and commercialize the most effective cannabis strains, backed by clinical data. This innovative research and development path aims to solve the critical need for real science to support claims surrounding medical marijuana. The company’s approach, combined with its strategic alliances, will effectively address the medical community’s concerns over the complexities of cannabis potency, efficacy, quality and content in the nearly 800 marijuana strains currently known in the world. Opportunities for innovation and scientific advancement related to the field of cannabis therapeutics will accelerate the knowledge base and provide a valuable alternative to the global opioid market that is estimated at nearly U.S. $35 billion. A growing negative opinion regarding the use of opioids for pain will continue to drive the need for alternative medical applications such as those provided by cannabis.
Veritas Pharma’s clinical cannabis development pipeline includes R&D for chronic pain, nausea, inflammation, muscle spasms, epilepsy and Post Traumatic Stress Disorder. The strategic alliance formed with Cannevert and its scientists will enable Veritas to be at the forefront of developing new and unique strains of medicinal cannabis. These plants, which they plan to patent protect for a variety of unmet medical needs, are destined to help patients suffering with chronic and debilitating symptoms of a variety of medical issues. Over 250 experiments have been performed so far with another 150 pharmacological and biological studies conducted. Veritas Pharma has also entered into an agreement with Sechelt Organic Marijuana Inc., which has a Licensed Producer application pending with Health Canada, to acquire 100 percent ownership in the company.
Results of the company’s research to date illustrate Veritas’ unique place in the medical marijuana industry. The company’s focus on the biological effect of the actual spectrum of cannabinoids sets Veritas apart as it seeks to patent and protect results-driven strains.
For more information, visit the company’s website at www.VeritasPharmaInc.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
No comments:
Post a Comment